Disposição a pagar de consumidores no Norte do Brasil para uma vacina hipotética contra o vírus da imunodeficiência humana

Abstract

The Human Immunodeficiency Virus (HIV) is considered one of the greatest public health challenges, due to its impact on morbidity and mortality. Currently, there is no vaccine avail-able for its prevention. However, the costs of any vaccine must be weighed against current preventive measures, as well as its impact on reducing future infections. This was the reason behind conducting a study of willingness to pay, to guide future financing decisions. Me-thods: A cross-sectional study was carried out, involving residents of the Northern Region of Brazil, regarding their willingness to pay for a hypothetical HIV vaccine with 70% effective-ness. 634 individuals were interviewed, 627 were considered eligible for the willingness to pay analysis and 94% agreed to be vaccinated with a hypothetical HIV vaccine, with a median maximum willingness to pay of R $ 200.00 (US $ 47.54) . Among the participants, 46% were male and 89.3% declared family income per capita below five minimum wages. Conclusion: It is believed that these findings may contribute to decision-making about prices, as soon as an HIV vaccine is available in Brazil.